On March 31, 2026, Aptose Biosciences Inc. held a Special Meeting of its shareholders where significant resolutions were passed. The shareholders voted overwhelmingly in favor of two key proposals. The first proposal, known as the Continuance Resolution, received 92.42% of the votes in favor, allowing the Corporation to continue its operations under the Business Corporations Act of Alberta, transitioning from the Canada Business Corporations Act. This move is expected to streamline operations and potentially enhance the company's governance structure.

The second proposal, the Arrangement Resolution, also saw strong support with 84.87% of votes in favor. This resolution pertains to a plan of arrangement where HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all outstanding common shares of Aptose that are not already owned by the Hanmi Purchasers or their affiliates. This acquisition is anticipated to provide Aptose with additional resources and strategic direction, aligning with its long-term growth objectives.

The results of the votes indicate a strong confidence from shareholders in the direction the company is taking, particularly in light of the strategic partnership with Hanmi Pharmaceutical. The approval of these resolutions is expected to positively influence Aptose's operational capabilities and market position moving forward. The company is now positioned to leverage this new structure to enhance its business operations and shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.